AstraZeneca Share Holder Equity 2010-2024 | AZN

AstraZeneca share holder equity from 2010 to 2024. Share holder equity can be defined as the sum of preferred and common equity items
  • AstraZeneca share holder equity for the quarter ending March 31, 2024 was $37.501B, a 4.72% increase year-over-year.
  • AstraZeneca share holder equity for 2023 was $39.166B, a 5.69% increase from 2022.
  • AstraZeneca share holder equity for 2022 was $37.058B, a 5.67% decline from 2021.
  • AstraZeneca share holder equity for 2021 was $39.287B, a 151.23% increase from 2020.
AstraZeneca Annual Share Holder Equity
(Millions of US $)
2023 $39,166
2022 $37,058
2021 $39,287
2020 $15,638
2019 $14,596
2018 $14,044
2017 $16,642
2016 $16,669
2015 $18,509
2014 $19,646
2013 $23,253
2012 $23,946
2011 $23,466
2010 $23,410
2009 $20,821
AstraZeneca Quarterly Share Holder Equity
(Millions of US $)
2024-03-31 $37,501
2023-12-31 $39,166
2023-09-30 $37,221
2023-06-30 $37,416
2023-03-31 $35,811
2022-12-31 $37,058
2022-09-30 $35,154
2022-06-30 $35,951
2022-03-31 $36,359
2021-12-31 $39,287
2021-09-30 $39,912
2021-06-30 $15,693
2021-03-31 $14,446
2020-12-31 $15,638
2020-09-30 $13,618
2020-06-30 $13,658
2020-03-31 $12,216
2019-12-31 $14,596
2019-09-30 $13,669
2019-06-30 $15,071
2019-03-31 $12,029
2018-12-31 $14,044
2018-09-30 $13,537
2018-06-30 $14,272
2018-03-31 $14,573
2017-12-31 $16,642
2017-09-30 $15,447
2017-06-30 $15,412
2017-03-31 $14,779
2016-12-31 $16,669
2016-09-30 $14,912
2016-06-30 $15,390
2016-03-31 $16,642
2015-12-31 $18,509
2015-09-30 $17,368
2015-06-30 $18,299
2015-03-31 $16,956
2014-12-31 $19,646
2014-09-30 $20,466
2014-06-30 $22,052
2014-03-31 $21,477
2013-12-31 $23,253
2013-09-30 $23,447
2013-06-30 $23,412
2013-03-31 $22,488
2012-12-31 $23,946
2012-09-30 $22,255
2012-06-30 $22,234
2012-03-31 $21,715
2011-12-31 $23,466
2011-09-30 $24,154
2011-06-30 $23,815
2011-03-31 $22,547
2010-12-31 $23,410
2010-09-30 $22,312
2010-06-30 $22,265
2010-03-31 $20,888
2009-12-31 $20,821
2009-09-30 $19,553
2009-06-30 $17,942
2009-03-31 $15,529
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $248.255B $45.811B
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $824.287B 119.14
Novo Nordisk (NVO) Denmark $642.884B 49.40
Johnson & Johnson (JNJ) United States $349.955B 13.90
Merck (MRK) United States $329.771B 60.00
AbbVie (ABBV) United States $293.293B 15.15
Novartis AG (NVS) Switzerland $215.744B 15.30
Pfizer (PFE) United States $156.738B 19.48
Sanofi (SNY) $122.543B 11.56
Innoviva (INVA) United States $0.993B 6.97